Stage II Follow-Up
After treatment, all patients with Stage II melanoma should receive a physical examination, including a skin examination, using the following schedule. Other scans and tests may be recommended.
|Type of Follow-up||Description|
Annually by healthcare provider
For Stage IIA patients:
For Stage IIB and Stage IIC patients:
For Stage IIA patients:
For Stage IIB and IIC patients:
For Stage IIA patients: None
For Stage IIB and IIC patients: Possibly annually
All patients with Stage IIA melanoma should have a skin examination once a year. A physical examination should be performed every 3-12 months for the first 5 years, then once a year as needed. The frequency of a physical examinations depends on the perceived level of risk for new primary melanomas and for the recurrence of the previous tumor. Imaging tests are performed only for specific symptoms.
All patients with Stage IIB and IIC melanoma should have a skin examination once a year. Patients should have a physical examination every 3-6 months for years 1-2, every 3-12 months for years 3-5, and then once a year as needed Imaging tests are recommended if specific signs of cancer appear. You may also receive imaging tests every 3-12 months to check for cancer recurrence that isn’t causing symptoms. Possible tests for screening include a chest x-ray, CT scan, and a PET/CT scan; and a brain MRI every year. These tests may be done for up to 5 years after treatment has ended. Imaging tests are not recommended after 5 years if there has been no recurrence and you don’t have any symptoms. If follow-up tests show that the cancer has come back, treatment options will depend on the type of recurrence.
With treatment, Stage II melanoma is considered intermediate- to high-risk for local recurrence or distant metastasis. Therefore, early detection of melanoma through skin self-examination and medical examination continues to be of the utmost importance
Large-scale studies have shown the following probabilities of disease-free survival. Keep in mind that the statistics shown for survival are averages; everyone’s cancer and survival rate is based on many factors and determined on an individual basis.
|5 years after treatment1||10 years after treatment1|
Stage IIA: 94%
Stage IIA: 88%
Stage IIB: 87%
Stage IIB: 82%
Stage IIC: 82%
Stage IIC: 75%
1. Gershenwald JE, Final Version of 2017 AJCC Melanoma Staging and Classification.